TB risk during biologic treatment with agents other than TNF-alpha inhibitors

2018-10-09
Gülen Hatemi

What is the risk of tuberculosis (TB) during biologic treatment with agents other than tumor necrosis factor (TNF)-alpha inhibitors?

Gülen Hatemi, MD: Interleukin (IL)-1 blockers are considered to be safe regarding the development of TB. But we actually have 2 patients who developed TB while using an anti–IL-1 blocker. IL-17 blockers really seem to be safe. There are data from psoriasis and psoriatic arthritis trials. As far as I remember, there were more than 2000 patients and none of them developed TB. With IL-6 blockers there can also be some risk of TB.

See also

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.